Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate‑to‑Severe Atopic Dermatitis
Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate‑to‑Severe Atopic Dermatitis Convoca: Pfizer Inc Termini: 13/05/2026
